Table of Contents

Research Articles

• Research Articles | AuthorChoice

  Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma

  Nathan Singh, Xiaojun Liu, Jessica Hulitt, Shuguang Jiang, Carl H. June, Stephan A. Grupp, David M. Barrett and Yangbing Zhao

  Cancer Immunol Res November 1 2014 2 (11) 1059-1070; DOI:10.1158/2326-6066.CIR-14-0051

  
  

  Singh and colleagues show that RNA-CAR T cells mediate rapid and long-term tumor destruction when delivered locally but not when delivered systemically due to the inability of RNA-CAR T cells to penetrate the tumor microenvironment.

• Research Articles

  Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

  Kelly G. Paulson, Andrew Tegeder, Christoph Willmes, Jayasri G. Iyer, Olga K. Afanasiev, David Schrama, Shinichi Koba, Renee Thibodeau, Kotaro Nagase, William T. Simonson, Aaron Seo, David M. Koelle, Margaret Madeleine, Shailender Bhatia, Hideki Nakajima, Shigetoshi Sano, James S. Hardwick, Mary L. Disis, Michele A. Cleary, Jürgen C. Becker and Paul Nghiem

  Cancer Immunol Res November 1 2014 2 (11) 1071-1079; DOI:10.1158/2326-6066.CIR-14-0005

  
  

  Paulson and colleagues report that 84% of Merkel cell carcinoma (MCC) tumors downregulated MHC-I expression, and MCC patients treated with intralesional IFNs had increased MHC-I expression on their tumor cells, thus promoting the use of immune-stimulating therapies for MCC.

• Research Articles | AuthorChoice

  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

  Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan and Samir N. Khleif

  Cancer Immunol Res November 1 2014 2 (11) 1080-1089; DOI:10.1158/2326-6066.CIR-14-0095

  
  

  Abu-Eid, Samara, and colleagues used PI3K–Akt pathway inhibitors to selectively disrupt homeostasis of immunosuppressive Tregs in naïve and tumor-bearing mice, and to enhance vaccine-induced antitumor immune responses, highlighting the therapeutic potential of these inhibitors as Treg-depleting reagents.

• Research Articles

  Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

  Benedetto Farsaci, Renee N. Donahue, Michael A. Coplin, Italia Grenga, Lauren M. Lepone, Alfredo A. Molinolo and James W. Hodge

  Cancer Immunol Res November 1 2014 2 (11) 1090-1102; DOI:10.1158/2326-6066.CIR-14-0076

  
  

  Farsaci, Donahue, and colleagues show that combining antiangiogenic tyrosine kinase inhibitors with vaccines increased tumor-infiltrating lymphocytes, decreased tumor density, and enhanced tumor oxygenation, indicating the potential of altering tumor architecture in cancer therapy.

• Research Articles

  IL4 Limits the Efficacy of Tumor-Targeted Antibody Therapy in a Murine Model

  Rishi Surana, Shangzi Wang, Wei Xu, Sandra A. Jablonski and Louis M. Weiner

  Cancer Immunol Res November 1 2014 2 (11) 1103-1112; DOI:10.1158/2326-6066.CIR-14-0103

  
  

  Surana and colleagues report that neutralizing IL4 altered the tumor microenvironment (TME) and enhanced the efficacy of the HER2-directed antibody trastuzumab, thus providing a rationale for targeting soluble mediators in the TME to enhance antitumor antibody therapy.

• Research Articles

  Murine Splenic CD4⁺ T Cells, Induced by Innate Immune Cell Interactions and Secreted Factors, Develop Antileukemia Cytotoxicity

  Megan E. Nelles, Joshua M. Moreau, Caren L. Furlonger, Alexandra Berger, Jeffrey A. Medin and Christopher J. Paige

  Cancer Immunol Res November 1 2014 2 (11) 1113-1124; DOI:10.1158/2326-6066.CIR-13-0208

  
  

  Nelles and colleagues show in a murine model of leukemia that each of the cytokines IL12, IFNγ, and MCP-1 has a role in guiding a cellular cascade of contactdependent cooperation of NKT cells and DCs that leads to activation of CD4⁺ cytotoxic T cells and elimination of leukemia.